AbbVie’s Rinvoq Leads Immunology Market as Physicians Rank Players, J&J Sees Decline

1. AbbVie has been ranked favorably among immunology players by physicians, while J&J has experienced a decline in this regard.
2. AbbVie's Rinvoq, a JAK inhibitor, has received its seventh FDA approval for Crohn's disease in less than four years, showcasing the company's efficiency in expanding its immunology blockbusters.
3. Rinvoq's approval history includes indications for rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, dermatitis, ankylosing spondylitis, axial spondyloarthritis, and now Crohn's disease.
4. Despite concerns about heart-related side effects associated with JAK inhibitors, Rinvoq has generated $2.5 billion in sales in 2023, a 52% increase from 2021.
5. AbbVie's advertising spend for Rinvoq in 2023 was $426 million, the second highest for a drug that year.
6. Rinvoq is the first JAK inhibitor endorsed for Crohn's disease, with clinical trial results showing early and long-term symptom relief and evidence of visible reduction in intestinal lining damage caused by excess inflammation.